1. Clinical Significance of Cancer Stem Cell Markers in Primary and Metastatic Tissues in Patients With Breast Cancer.
- Author
-
Yamanaka T, Oshima T, Murayama D, Okamoto S, Matsui AI, Yasukawa M, Matsubara Y, Toda S, Hiroshima Y, Aoyama T, Suganuma N, Rino Y, Saito A, Miyagi Y, Iwasaki H, and Yamashita T
- Subjects
- Neoplasm Metastasis, Aldehyde Dehydrogenase 1 Family metabolism, Retinal Dehydrogenase metabolism, AC133 Antigen metabolism, Hyaluronan Receptors metabolism, Nerve Tissue Proteins metabolism, RNA-Binding Proteins metabolism, Humans, Female, Middle Aged, Disease-Free Survival, Japan, Neoplastic Stem Cells metabolism, Breast Neoplasms metabolism, Breast Neoplasms pathology, Biomarkers, Tumor metabolism
- Abstract
Background/aim: This study aimed to examine the clinical significance of the protein expression of the cancer stem cell (CSC) markers ALDH1A1, CD133, CD44, and MSI-1 in primary and metastatic tissues of patients with breast cancer (BC)., Patients and Methods: ALDH1A1, CD133, CD44, and MSI-1 protein expression in pairs of primary and metastatic tissues of 55 patients with BC with metastases treated at Kanagawa Cancer Center between January 1970 and December 2016 were evaluated using immunohistochemical assay and their association with clinicopathological factors and survival was examined., Results: There were no significant differences in CSC marker expression rates between primary and metastatic tissues for any CSC markers. Regarding the relationship between CSC marker expression in primary tissues and survival, patients with high CD133 expression had significantly lower recurrence-free survival (DFS) and overall survival. On multivariate analysis, they were also a poor independent predictor of DFS (hazard ratio=4.993, 95%CI=2.189-11.394, p=0.0001). In contrast, there was no significant association between the expression of any CSC marker in metastatic tissues and survival., Conclusion: CD133 expression in the primary BC tissue may be a useful risk factor for recurrence in patients with BC., (Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF